A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B

NCT06566248 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: TQA3810 tablets+NUC
DRUG: Placebo+NUC

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.